Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.39 |
| ▸ | LPL | P06858 | 5/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | BTK | Q06187 | 3/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 4/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL251382 | 0.74 | LIPG (0.48) | LIPGLPLROCK1BACE1IRAK4 | |
| SCHEMBL28061273 | 0.73 | LIPG (0.47) | LIPGLPLROCK1BACE1IRAK4 | |
| SCHEMBL29790543 | 0.73 | LIPG (0.49) | LIPGLPLBACE1IRAK4 | |
| SCHEMBL5779763 | 0.73 | LIPG (0.49) | LIPGLPLBACE1IRAK4 | |
| SCHEMBL20504061 | 0.71 | ADRA1D (0.40) | LIPGLPLJAK2BTKBACE1 | |
| SCHEMBL1807291 | 0.70 | LIPG (0.47) | LIPGLPLIRAK4 | |
| SCHEMBL861033 | 0.70 | LIPG (0.47) | LIPGLPLIRAK4 | |
| SCHEMBL28817154 | 0.70 | LIPG (0.47) | LIPGLPLBACE1IRAK4EGFR | |
| SCHEMBL1803521 | 0.70 | LIPG (0.47) | LIPGLPLIRAK4 | |
| SCHEMBL28645604 | 0.69 | LPL (0.37) | LIPGLPLJAK2BTKROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238163-A1 | CRYSTAL FORM OF C-MET INHIBITOR AND SALT FORM THEREOF AND PREPARATION METHOD THEREFOR | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238163-A1 | CRYSTAL FORM OF C-MET INHIBITOR AND SALT FORM THEREOF AND PREPARATION METHOD THEREFOR | MET, HGF, HGFAC | LIPG 3503/4885LPL 4399/4885JAK2 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.